1. Home
  2. AERT vs CGTX Comparison

AERT vs CGTX Comparison

Compare AERT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aeries Technology Inc.

AERT

Aeries Technology Inc.

HOLD

Current Price

$6.98

Market Cap

39.7M

ML Signal

HOLD

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$0.95

Market Cap

79.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AERT
CGTX
Founded
2012
2007
Country
Singapore
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
79.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
AERT
CGTX
Price
$6.98
$0.95
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
15.1K
369.4K
Earning Date
02-09-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
110.87
62.79
EPS
0.27
N/A
Revenue
$70,014,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$25.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.55
52 Week High
$7.65
$2.05

Technical Indicators

Market Signals
Indicator
AERT
CGTX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
AERT
CGTX

About AERT Aeries Technology Inc.

Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs. It has more than 40 clients spanning across industry segments.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: